개방각 녹내장(OAG) 시장 : 인사이트, 경쟁 환경 및 시장 예측(2030년)

Open Angle Glaucoma (OAG) Market By Type (Primary Open Angle Glaucoma, Secondary Open Angle Glaucoma, And Others), Treatment (Drugs And Devices), And Geography (North America, Europe, Asia-Pacific, And Rest Of The World) is expected to grow at a steady CAGR forecast till 2030 owing to the growing prevalence of glaucoma and the rising geriatric population

The global Open Angle Glaucoma (OAG) Market is estimated to grow at a CAGR of 6.87% during the forecast period from 2024 to 2030. The demand for Open Angle Glaucoma (OAG) is primarily being boosted by the growing prevalence of glaucoma globally, increasing product development activities for glaucoma drugs and devices, and the rising geriatric population with a variety of eye disorders, during the forecast period from 2024-2030.

Open Angle Glaucoma (OAG) Market Dynamics:

According to the World Health Organization (WHO) 2021, the prevalence rate of unaddressed glaucoma in the year 2020 was 7.7 million globally. Moreover, as per the World Glaucoma Association 2021, the worldwide prevalence reported in 2020 was estimated to be approximately 79.6 million. As per the same source, the number is likely to increase to 111.8 million individuals by 2040. The increasing number of people getting affected with glaucoma is expected to drive the demand for open angle glaucoma in the upcoming years, thus resulting in the positive growth of the Open Angle Glaucoma (OAG) market.

Further, the presence of various implants in the research & developmental phase will create significant opportunities in order to drive the market for open angle glaucoma. For instance, in February 2022, PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants, announced the Phase IIa study of its PA5108 Ocular Implant for the treatment of Primary Open-Angle Glaucoma (POAG) met both the study's primary and secondary efficacy endpoints of at least 20% IOP lowering in its low dose cohort. The PA5108 ocular implant employs the proprietary Prezia(TM) Sustained Drug Delivery Technology to release a constant daily dose of latanoprost free acid.

Thus, due to the interplay of all the above-mentioned factors, the demand for Open Angle Glaucoma (OAG) drugs and devices will increase, thus resulting in the overall growth of the Open Angle Glaucoma (OAG) market.

However, the various side effects associated with open angle glaucoma treatment, and the high cost of open angle glaucoma procedures, may act as factors that are expected to limit the growth of the Open Angle Glaucoma (OAG) market.

Open Angle Glaucoma (OAG) Market Segment Analysis:

Open Angle Glaucoma (OAG) Market By Type (Primary Open Angle Glaucoma, Secondary Open Angle Glaucoma, and Others), Treatment (Drugs and Devices), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the type segment of the Open Angle Glaucoma (OAG) market, the primary open angle glaucoma category is estimated to amass a significant revenue share in the Open Angle Glaucoma (OAG) market in 2023. This can be attributed to the large patient population associated with open angle glaucoma and the rising product development activities specific to this category, in the upcoming years.

Primary open-angle glaucoma is associated with optic nerve damage, where it involves an open anterior chamber angle and an elevated or average intraocular pressure (IOP). This progressive condition could even lead to blindness if left untreated. Treatment of primary open-angle glaucoma includes laser surgery and/or topical medications like prostaglandin analogs and beta-blockers. Incisional surgery may be necessary to increase aqueous drainage in some cases. Thus, the serious consequences of primary open-angle glaucoma in patients is expected to spur the market demand for primary open angle glaucoma.

Moreover, in September 2022, Santen and UBE announced that the FDA approved Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension.

Therefore, owing to the various product development activities and growing cases associated with primary open angle glaucoma, this category is expected to drive the overall growth of the Open Angle Glaucoma (OAG) market during the forecast period.

North America Is Expected To Dominate The Overall Open Angle Glaucoma (OAG) Market:

North America is expected to account for the highest proportion of the Open Angle Glaucoma (OAG) Market in 2023, out of all regions. This is due to the presence of a large patient pool suffering from glaucoma and its risk factors in North America. Additionally, the increasing incidence of other eye disorders, the growing geriatric population, and the presence of developed and sophisticated healthcare infrastructure in the region are some of the key factors driving the growth of the Open Angle Glaucoma (OAG) market in North America.

As per data by the Centers for Disease Control and Prevention (CDC) 2020, in the United States, cases of glaucoma are expected to reach 5.5 million by 2050. Also, according to the National Diabetics Statistics Report by the Centers for Disease Control and Prevention (CDC, 2020), about 34.2 million Americans had diabetes in 2020. The report further stated that approximately 88 million Americans showed pre-diabetes levels.

The CDC considers diabetes to be one of the major risk factors that may lead to glaucoma development. This will increase the demand for glaucoma treatment, thus further driving the demand for open-angle glaucoma across North America.

In addition, the various regulatory approvals for open-angle glaucoma products by the FDA are also expected to propel the market demand for open-angle glaucoma. For example, in March 2020, Allergan, part of AbbVie Inc., received the US FDA clearance for DURYSTA(TM) (bimatoprost implant), the first biodegradable sustained-release implant for the treatment of open-angle glaucoma. Thus, the rising incidence of glaucoma in North America along with the various product development activities taking place will eventually drive the overall market for Open Angle Glaucoma (OAG) in North America during the forecast period.

Open Angle Glaucoma (OAG) Market Key Players:

Some of the key market players operating in the Open Angle Glaucoma (OAG) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Eyepoint Pharmaceuticals, Inc., Iridex Corporation, Glaukos Corporation, Alcon Inc., Aerie Pharmaceuticals, Abbvie, Inc., Bausch Health Companies Inc., Fera Pharmaceuticals, Amorphex Therapeutics Holdings, Inc, Kubota Vision Inc., iSTAR Medical, Bayer AG, Carl Zeiss Meditec AG, Nidek Co Ltd, Accutome, Inc, AqueSys, and others.

Recent Developmental Activities In The Open Angle Glaucoma (OAG) Market:

• In December 2023, the U.S. Food and Drug Administration approved a new treatment for glaucoma, iDose(R) TR (travoprost intracameral implant, 75 mcg). It is a first-of-its-kind treatment that is designed to provide up to three years of continuous drug therapy directly inside the eye, helping people with glaucoma take control over the elevated eye pressure associated with this vision disease.
• In July 2022, AbbVie and iSTAR Medical SA, announced a strategic transaction to further develop and commercialize iSTAR Medical's MINIject(R) device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. This complementary alliance supported iSTAR Medical's development and commercial efforts for MINIject(R).
• In December 2023, iSTAR Medical introduced its MINIject device for the treatment of patients with glaucoma, in the Netherlands. As part of the device introduction in the region, the company successfully carried out the first device implantations for glaucoma patients at the University Eye Clinic of the Maastricht University Medical Center+ in the country.

Key Takeaways From The Open Angle Glaucoma (OAG) Market Report Study

• Market size analysis for current Open Angle Glaucoma (OAG) Market size (2023), and market forecast for 6 years (2024-2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global Open Angle Glaucoma (OAG) market.
• Various opportunities available for the other competitors in the Open Angle Glaucoma (OAG) Market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current Open Angle Glaucoma (OAG) market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Open Angle Glaucoma (OAG) market growth in the coming future?

Target Audience Who Can Be Benefited From This Open Angle Glaucoma (OAG) Market Report Study

• Open Angle Glaucoma (OAG) product providers
• Research organizations and consulting companies
• Open Angle Glaucoma (OAG)-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Open Angle Glaucoma (OAG)
• Various end-users who want to know more about the Open Angle Glaucoma (OAG) Market and the latest technological developments in the Open Angle Glaucoma (OAG) Market.

Frequently Asked Questions For The Open Angle Glaucoma (OAG) Market:

1. What are Open Angle Glaucoma (OAG)?

Open-angle glaucoma (OAG) is an irreversible optic neuropathy characterized by peripheral visual loss that usually precedes central vision loss. Due to its chronic nature and lack of early indicators of disease progression, OAG is a major health concern worldwide.

2. What is the market for Open Angle Glaucoma (OAG)?

The global Open Angle Glaucoma (OAG) Market is estimated to grow at a CAGR of 6.87% during the forecast period from 2024 to 2030.

3. What are the drivers for the global Open Angle Glaucoma (OAG) market?

The Open Angle Glaucoma (OAG) Market is slated to witness prosperity owing to the growing prevalence of glaucoma globally, increasing product development activities for glaucoma drugs and devices, and the rising geriatric population with a variety of eye disorders, during the forecast period from 2024-2030.

4. Who are the key players operating in the global Open Angle Glaucoma (OAG) market?

Some of the key market players operating in the Open Angle Glaucoma (OAG) include Pfizer Inc., Novartis AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Eyepoint Pharmaceuticals, Inc., Iridex Corporation, Glaukos Corporation, Alcon Inc., Aerie Pharmaceuticals, Abbvie, Inc., Bausch Health Companies Inc., Fera Pharmaceuticals, Amorphex Therapeutics Holdings, Inc, Kubota Vision Inc., iSTAR Medical, Bayer AG, Carl Zeiss Meditec AG, Nidek Co Ltd, Accutome, Inc, AqueSys, and others.

5. Which region has the highest share in the global Open Angle Glaucoma (OAG) market?

North America is expected to dominate the overall Open Angle Glaucoma (OAG) market during the forecast period from 2024 to 2030. This is due to the presence of a large patient pool suffering from glaucoma and its risk factors in North America. Additionally, the increasing incidence of other eye disorders, the growing geriatric population, and the presence of developed and sophisticated healthcare infrastructure in the region are some of the key factors driving the growth of the Open Angle Glaucoma (OAG) market in North America.

Table of Contents

1. Open Angle Glaucoma (OAG) Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Open Angle Glaucoma (OAG) Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Open Angle Glaucoma (OAG) Market Key Factors Analysis

• 5.1. Open Angle Glaucoma (OAG) Market Drivers
  • 5.1.1. Growing prevalence of Glaucoma globally
  • 5.1.2. Increasing product development activities for glaucoma drugs and devices
  • 5.1.3. Rising Geriatric Population
• 5.2. Open Angle Glaucoma (OAG) Market Restraints and Challenges
  • 5.2.1. Side effects associated with Open Angle Glaucoma (OAG) treatment
  • 5.2.2. High Cost of Open Angle Glaucoma (OAG) Procedures
• 5.3. Open Angle Glaucoma (OAG) Market Opportunities
  • 5.3.1. Increasing awareness of eye health, check-ups, and remote monitoring

6. Open Angle Glaucoma (OAG) Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Open Angle Glaucoma (OAG) Market Assessment

• 7.1. By Type
  • 7.1.1. Primary Open Angle Glaucoma
  • 7.1.2. Secondary Open Angle Glaucoma
  • 7.1.3. Others
• 7.2. By Treatment
  • 7.2.1. Drugs
  • 7.2.2. Devices
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. United States Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
    • 7.3.1.2. Canada Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
    • 7.3.1.3. Mexico Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
  • 7.3.2. Europe
    • 7.3.2.1. France Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
    • 7.3.2.2. Germany Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
    • 7.3.2.3. United Kingdom Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
    • 7.3.2.4. Italy Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
    • 7.3.2.5. Spain Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
    • 7.3.2.6. Rest of Europe Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. China Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
    • 7.3.3.2. Japan Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
    • 7.3.3.3. India Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
    • 7.3.3.4. Australia Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
    • 7.3.3.5. South Korea Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
    • 7.3.3.6. Rest of Asia-Pacific Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. Middle East Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
    • 7.3.4.2. Africa Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)
    • 7.3.4.3. South America Open Angle Glaucoma (OAG) Market Size in USD million (2021-2030)

8. Open Angle Glaucoma (OAG) Market Company and Product Profiles

• 8.1. Pfizer Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Novartis AG
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Merck & Co. Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Teva Pharmaceutical Industries Ltd.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Eyepoint Pharmaceuticals, Inc.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Iridex Corporation
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Glaukos Corporation
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Alcon Inc.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Aerie Pharmaceuticals
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Abbvie, Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Bausch Health Companies Inc.
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Fera Pharmaceuticals
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Amorphex Therapeutics Holdings, Inc
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Kubota Vision Inc.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. iSTAR Medical
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Bayer AG
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Carl Zeiss Meditec AG
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Nidek Co Ltd
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Accutome, Inc
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. AqueSys
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us